Efficacy and safety evaluation of citalopram and doxepin on sleep quality in comorbid insomnia and anxiety disorders

Experimental and Therapeutic Medicine

Volumn 10, Issue 4, 2015, Pages 1303-1308

  Wu, Junfeng ^a   Chang, Fei ^a   Zu, Hengbing ^a  

^a JINSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

Anxiety disorders; Citalopram; Doxepin; Insomnia

Indexed keywords

CITALOPRAM; DOXEPIN;

ADULT; ANXIETY DISORDER; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; ELEVATED BLOOD PRESSURE; FEMALE; HAMILTON ANXIETY SCALE; HEADACHE; HEART PALPITATION; HUMAN; HYPEREXCITABILITY; INSOMNIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA AND VOMITING; PARESTHESIA; PERSONALITY DISORDER; PITTSBURGH SLEEP QUALITY INDEX; POLLAKISURIA; RANDOMIZED CONTROLLED TRIAL; SLEEP QUALITY; SOMNOLENCE;

EID: 84940556568     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2686     Document Type: Article

References (26)

1. Watson D: Rethinking the mood and anxiety disorders: A quantitative hierarchical model for DSM-V. J Abnorm Psychol 114: 522-536, 2005.
2. Barlow DH: Unraveling the mysteries of anxiety and its disorders from the perspective of emotion theory. Am Psychol 55: 1247-1263, 2000.
3. van Mill JG, Hoogendijk WJ, Vogelzangs N, van Dyck R and Penninx BW: Insomnia and sleep duration in a large cohort of patients with major depressive disorder and anxiety disorders. J Clin Psychiatry 71: 239-246, 2010.
4. Uhde TW, Cortese BM and Vedeniapin A: Anxiety and sleep problems: Emerging concepts and theoretical treatment implications. Curr Psychiatry Rep 11: 269-276, 2009.
5. Papadimitriou GN and Linkowski P: Sleep disturbance in anxiety disorders. Int Rev Psychiatry 17: 229-236, 2005.
6. Marcks BA, Weisberg RB, Edelen MO and Keller MB: The relationship between sleep disturbance and the course of anxiety disorders in primary care patients. Psychiatry Res 178: 487-492, 2010.
7. Cunnington D, Junge MF and Fernando AT: Insomnia: Prevalence, consequences and effective treatment. Med J Aust 199: S36-S40, 2013.
8. Hyttel J: Citalopram-pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 6: 277-295, 1982.
9. Jindal RD and Thase ME: Treatment of insomnia associated with clinical depression. Sleep Med Rev 8: 19-30, 2004.
10. Shahsavand-Ananloo E, Berenji F, Sadeghniiat K, Alimadadi A, Zahiroddin AR, Tabatabaee M, Abbasi-Asl M and Ghaeli P: Comparing effects of citalopram with fluoxetine on sleep quality in patients with major depressive disorder. Eur Rev Med Pharmacol Sci 17: 1155-1161, 2013.
11. Hajak G, Rodenbeck A, Voderholzer U, Riemann D, Cohrs S, Hohagen F, Berger M and Rüther E: Doxepin in the treatment of primary insomnia: A placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry 62: 453-463, 2001.
12. Weber J, Siddiqui MA, Wagstaff AJ and McCormack PL: Low-dose doxepin: In the treatment of insomnia. CNS Drugs 24: 713-720, 2010.
13. Buysse DJ, Reynolds CF III, Monk TH, Berman SR and Kupfer DJ: The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research. Psychiatry Res 28: 193-213, 1989.
14. Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 32: 50-55, 1959.
15. Sivertsen B, Krokstad S, Øverland S and Mykletun A: The epidemiology of insomnia: Associations with physical and mental health. The HUNT-2 study. J Psychosom Res 67: 109-116, 2009.
16. Taylor DJ, Lichstein KL, Durrence HH, Reidel BW and Bush AJ: Epidemiology of insomnia, depression and anxiety. Sleep 28: 1457-1464, 2005.
17. Harvey AG: A cognitive model of insomnia. Behav Res Ther 40: 869-893, 2002.
18. Monaca C, Boutrel B, Hen R, Hamon M and Adrien J: 5-HT 1A/1B receptor-mediated effects of the selective serotonin reuptake inhibitor, citalopram, on sleep: Studies in 5-HT 1A and 5-HT 1B knockout mice. Neuropsychopharmacology 28: 850-856, 2003.
19. Vazquez-Palacios G, Hernández-González M, Guevara Pérez MA and Bonilla-Jaime H: Nicotine and fluoxetine induce arousing effects on sleep-wake cycle in antidepressive doses: A possible mechanism of antidepressant-like effects of nicotine. Pharmacol Biochem Behav 94: 503-509, 2010.
20. Fava M, McCall WV, Krystal A, Wessel T, Rubens R, Caron J, Amato D and Roth T: Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 59: 1052-1060, 2006.
21. Roth T, Zorick F, Wittig R, McLenaghan A and Roehrs T: The effects of doxepin HCl on sleep and depression. J Clin Psychiatry 43: 366-368, 1982.
22. Krystal AD, Durrence HH, Scharf M, Jochelson P, Rogowski R, Ludington E and Roth T: Efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep 33: 1553-1561, 2010.
23. Roth T, Heith Durrence H, Jochelson P, Peterson G, Ludington E, Rogowski R, Scharf M and Lankford A: Efficacy and safety of doxepin 6 mg in a model of transient insomnia. Sleep Med 11: 843-847, 2010.
24. Krystal AD, Lankford A, Durrence HH, Ludington E, Jochelson P, Rogowski R and Roth T: Efficacy and safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in adults with chronic primary insomnia. Sleep 34: 1433-1442, 2011.
25. Haas HL, Sergeeva OA and Selbach O: Histamine in the nervous system. Physiol Rev 88: 1183-1241, 2008.
26. Goforth HW: Low-dose doxepin for the treatment of insomnia: Emerging data. Expert Opin Pharmacother 10: 1649-1655, 2009.